DE60320979D1 - Impfstoffe gegen Pilzen aus Beta-Glucan - Google Patents

Impfstoffe gegen Pilzen aus Beta-Glucan

Info

Publication number
DE60320979D1
DE60320979D1 DE60320979T DE60320979T DE60320979D1 DE 60320979 D1 DE60320979 D1 DE 60320979D1 DE 60320979 T DE60320979 T DE 60320979T DE 60320979 T DE60320979 T DE 60320979T DE 60320979 D1 DE60320979 D1 DE 60320979D1
Authority
DE
Germany
Prior art keywords
glucan
antibodies
protective
presented
mushroom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60320979T
Other languages
German (de)
English (en)
Inventor
Luciano Polonelli
Antonio Cassone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE60320979D1 publication Critical patent/DE60320979D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DE60320979T 2002-05-15 2003-05-15 Impfstoffe gegen Pilzen aus Beta-Glucan Expired - Lifetime DE60320979D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0211118.5A GB0211118D0 (en) 2002-05-15 2002-05-15 Vaccines
PCT/IB2003/002460 WO2003097091A2 (en) 2002-05-15 2003-05-15 Glucan-based vaccines

Publications (1)

Publication Number Publication Date
DE60320979D1 true DE60320979D1 (de) 2008-06-26

Family

ID=9936711

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60320979T Expired - Lifetime DE60320979D1 (de) 2002-05-15 2003-05-15 Impfstoffe gegen Pilzen aus Beta-Glucan
DE60336027T Expired - Lifetime DE60336027D1 (de) 2002-05-15 2003-05-15 Impfstoffe auf mannoproteinfreier Beta-Glucan-Basis

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60336027T Expired - Lifetime DE60336027D1 (de) 2002-05-15 2003-05-15 Impfstoffe auf mannoproteinfreier Beta-Glucan-Basis

Country Status (14)

Country Link
US (4) US20050208079A1 (enExample)
EP (2) EP1891970B1 (enExample)
JP (3) JP5110767B2 (enExample)
AT (2) ATE497781T1 (enExample)
AU (1) AU2003241104A1 (enExample)
CA (2) CA2485847C (enExample)
CY (1) CY1108234T1 (enExample)
DE (2) DE60320979D1 (enExample)
DK (1) DK1506009T3 (enExample)
ES (1) ES2306871T3 (enExample)
GB (1) GB0211118D0 (enExample)
PT (1) PT1506009E (enExample)
SI (1) SI1506009T1 (enExample)
WO (1) WO2003097091A2 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7906492B2 (en) 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US8071552B2 (en) * 2004-04-05 2011-12-06 Universite Bordeaux 2 Peptides and peptidomimetics binding to CD23
GB0420466D0 (en) * 2004-09-14 2004-10-20 Cassone Antonio Anti-glucan antibodies
PL2878307T3 (pl) 2005-06-27 2020-01-31 Glaxosmithkline Biologicals S.A. Kompozycja immunogenna
WO2007084661A2 (en) * 2006-01-17 2007-07-26 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US8323644B2 (en) * 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
WO2007127668A2 (en) * 2006-04-26 2007-11-08 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
WO2009134891A2 (en) * 2008-04-29 2009-11-05 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof
US9457047B2 (en) 2006-11-06 2016-10-04 Whitehead Institute Immunomodulating compositions and methods of use thereof
ES2397186T3 (es) * 2006-11-06 2013-03-05 Whitehead Institute Composiciones inmunomoduladoras y métodos para su uso
AU2013203785B2 (en) * 2006-11-06 2016-11-17 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof
JP4687644B2 (ja) 2006-12-22 2011-05-25 富士ゼロックス株式会社 画像処理装置、画像読取装置及び画像形成装置
US9439954B2 (en) 2007-11-26 2016-09-13 Glaxosmithkline Biologicals Sa Conjugated beta-1,3-linked glucans
CA2706617A1 (en) † 2007-11-26 2009-06-25 Novartis Ag Adjuvanted glucans
US20110236489A1 (en) 2008-09-18 2011-09-29 Novartis Ag Vaccine adjuvant combinations
NL1036661C2 (en) 2009-03-04 2010-09-07 Serrix B V Anti-fungal compounds & compositions.
JP2012520289A (ja) * 2009-03-10 2012-09-06 パルメッド テバ リミテッド 新規なコプリヌス・コマトゥスおよびトレメッラ・メセンテリカキノコ菌株、それらの生産物および抽出物、ならびにそれらを含む組成物
CN102740882A (zh) 2009-08-27 2012-10-17 诺华有限公司 含有铝、寡核苷酸和聚阳离子的佐剂
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
WO2011035205A2 (en) 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
EA201291091A1 (ru) * 2010-05-14 2013-05-30 Олтек, Инк. Компоненты клеточной стенки дрожжей и их обнаружение
CN105999275A (zh) 2010-09-01 2016-10-12 诺华有限公司 免疫增强剂吸附不溶性金属离子
US9618508B2 (en) 2010-12-14 2017-04-11 Glaxosmithkline Biologicals Sa Flow cytometry analysis of materials adsorbed to metal salts
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
US9149541B2 (en) 2011-07-08 2015-10-06 Novartis Ag Tyrosine ligation process
JP6170932B2 (ja) 2011-11-07 2017-07-26 ノバルティス アーゲー ｓｐｒ００９６抗原およびｓｐｒ２０２１抗原を含むキャリア分子
HRP20161354T1 (hr) 2012-03-07 2016-12-02 Glaxosmithkline Biologicals Sa Argininske soli agonista tlr7
JP2015510872A (ja) 2012-03-07 2015-04-13 ノバルティス アーゲー Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤
US9375471B2 (en) 2012-03-08 2016-06-28 Glaxosmithkline Biologicals Sa Adjuvanted formulations of booster vaccines
US10092646B2 (en) * 2012-04-30 2018-10-09 Biothera, Inc. Compositions and methods for beta-glucan immunotherapy
TR201807340T4 (tr) 2013-02-01 2018-06-21 Glaxosmithkline Biologicals Sa Çan benzeri reseptör agonistleri içeren immünolojik kompozisyonların intradermal yoldan verilmesi.
CN103083663B (zh) * 2013-02-04 2014-12-10 江苏省农业科学院 一种免疫增强剂、灭活疫苗及其制备方法
US20160017062A1 (en) 2013-03-12 2016-01-21 Wellstat Vaccines, Llc Antibodies targeted to fungal cell wall polysaccharides
CN105593238B (zh) 2013-07-11 2020-09-08 诺华股份有限公司 使用微生物转谷氨酰胺酶进行赖氨酸特异性化学酶法蛋白质修饰
US9885726B2 (en) * 2013-12-05 2018-02-06 Biothera, Inc. β-glucan assay methods
ES2857557T3 (es) * 2015-01-26 2021-09-29 Kaleido Biosciences Inc Compuestos terapéuticos de glicano y métodos relacionados de los mismos
CN104771498A (zh) * 2015-03-13 2015-07-15 臧海阳 一种治疗热毒蕴结型痄腮的中药组合物
US11815435B2 (en) 2017-02-24 2023-11-14 Hibercell, Inc. Beta glucan immunopharmacodynamics
KR102795692B1 (ko) * 2018-01-19 2025-04-16 밀테니 비오텍 비.브이. & 씨오. 케이지 키메라 항원 수용체를 발현하는 조절 t 세포
US11701417B2 (en) * 2019-03-27 2023-07-18 West Virginia University Vaccine formulation to protect against pertussis
WO2023002252A1 (en) 2021-07-21 2023-01-26 Bioatlantis Limited Composition comprising beta-glucans and alpha-fucans for improving gut health and animal performance and methods of making the same
AU2023225283A1 (en) 2022-02-28 2024-08-22 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN.
EP4486387A1 (en) 2022-02-28 2025-01-08 Tridem Bioscience GmbH & Co KG A conjugate consisting of or comprising at least a ss-glucan or a mannan

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE466289B (sv) * 1984-09-19 1992-01-27 James Hoffman Makrofagstimulerande komposition jaemte foerfarande foer dess framstaellning
JPS6383012A (ja) * 1986-09-26 1988-04-13 Nonogawa Shoji:Kk 化粧料
JPH05503952A (ja) * 1989-09-08 1993-06-24 アルファ　ベータ　テクノロジー，インコーポレイティッド 可溶性グルカン類の製造方法
EP0471954A3 (en) 1990-08-13 1993-03-03 American Cyanamid Company Immunogenic conjugates of nontoxic oligosaccharide derived from bordetella pertussis lipooligosaccharide
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
ATE280235T1 (de) * 1993-03-05 2004-11-15 Wyeth Corp Plasmid zur herstellung von crm-protein und diphtherie-toxin
CN1094288A (zh) * 1993-04-23 1994-11-02 福建省微生物研究所 利用红色诺卡氏菌制造细胞壁骨架粉末的方法
NO300692B1 (no) 1994-04-29 1997-07-07 Biotec Mackzymal As Solubilisert forgrenet ß-1,3-glukan og anvendelse derav samt anvendelse av usolubilisert forgrenet ß-1,3-glukan
US6309642B1 (en) * 1997-04-28 2001-10-30 The Research And Development Institute, Inc. Peptides which mimic candida carbohydrate epitopes and their use in a vaccine
AUPN166195A0 (en) * 1995-03-13 1995-04-06 Norvet Research Pty Limited Process for glucan extraction
JPH09309842A (ja) * 1996-05-20 1997-12-02 Kureha Chem Ind Co Ltd 新規な生理活性物質、その製造方法及び医薬組成物
AU760669B2 (en) * 1998-04-28 2003-05-22 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
GB9925559D0 (en) * 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
JP4230635B2 (ja) 2000-02-29 2009-02-25 富士フイルム株式会社 デジタルカメラ

Also Published As

Publication number Publication date
CA2485847C (en) 2013-12-31
JP2005535298A (ja) 2005-11-24
US7824688B2 (en) 2010-11-02
JP2010131017A (ja) 2010-06-17
JP2012224636A (ja) 2012-11-15
CY1108234T1 (el) 2014-02-12
US20050208079A1 (en) 2005-09-22
PT1506009E (pt) 2008-08-14
HK1069125A1 (en) 2005-05-13
ATE497781T1 (de) 2011-02-15
ATE395080T1 (de) 2008-05-15
US20130171187A1 (en) 2013-07-04
CA2485847A1 (en) 2003-11-27
US20110059120A1 (en) 2011-03-10
DK1506009T3 (da) 2008-09-01
WO2003097091A3 (en) 2004-03-04
HK1114335A1 (en) 2008-10-31
GB0211118D0 (en) 2002-06-26
AU2003241104A1 (en) 2003-12-02
EP1891970B1 (en) 2011-02-09
SI1506009T1 (sl) 2008-10-31
ES2306871T3 (es) 2008-11-16
EP1506009B1 (en) 2008-05-14
US8679506B2 (en) 2014-03-25
WO2003097091A2 (en) 2003-11-27
CA2830619A1 (en) 2003-11-27
EP1506009A2 (en) 2005-02-16
DE60336027D1 (de) 2011-03-24
JP5684758B2 (ja) 2015-03-18
US8398990B2 (en) 2013-03-19
US20070141088A1 (en) 2007-06-21
EP1891970A1 (en) 2008-02-27
JP5110767B2 (ja) 2012-12-26

Similar Documents

Publication Publication Date Title
DE60320979D1 (de) Impfstoffe gegen Pilzen aus Beta-Glucan
YU73503A (sh) Preparati insulina koji ne sadrže cink ili sadrže male količine cinka i koji imaju poboljšanu stabilnost
PL377146A1 (pl) Cytokiny ochronne dla tkanek do ochrony, odnowy i wzmacniania reaktywnych komórek, tkanek i narządów
WO2004108093A3 (en) Antiseptic compositions, methods and systems
EP2289549A3 (en) Immunoconjugates for treating cancer
WO2003045306A3 (en) Phenoxy amine compounds and compositions for delivering active agents
AU2001257444A1 (en) Methods and compositions for enhancing cellular function through protection of tissue components
WO2005000241A3 (en) Compositons and methods for topical administration
CA2378892A1 (en) Preserved pharmaceutical formulations
TW200514580A (en) Adhesive preparations
CA2333601A1 (en) Surfactant for use in external preparations for skin and external preparation for skin containing the same
WO2004087098A3 (en) Preserved ophthalmic compositions
WO2003082926A3 (en) Antimicrobial polymer conjugates
WO2004009038A3 (de) Kosmetische zubereitungen mit antibakteriellen eigenschaften glyzyrrhetinsäure enthaltend
EA200501828A1 (ru) Тканепротекторные цитокины с увеличенным терапевтическим окном для защиты, восстановления и стимулирования реагирующих клеток, тканей и органов
TW200505437A (en) Composition possessing autonomic nerve function regulating action and use thereof
ATE273704T1 (de) Ophthalmische histamin-enthaltende zusammensetzungen und deren verwendung
WO2003009859A1 (en) Immunotherapy for humans
ITMI20031714A1 (it) Formazioni ad azione antitumorale.
WO2001043748A3 (en) Implant composition containing melengestrol acetate and trenbolone acetate
WO2004006851A3 (en) Mycoplasma gallisepticum formulation
WO2006121717A3 (en) Skin care compositions containing idebenone
WO2002055022A3 (en) Active metabolite of antifungal compound
WO2007140146A3 (en) Antimicrobial composition of 3-iodo-2-propynylbutyl carbamate and 1,3-butylene glycol as solvent
NZ584942A (en) Injectable meclizine formulations and methods comprising a molar excess of a modified cyclodextrin

Legal Events

Date Code Title Description
8364 No opposition during term of opposition